Efficiency of CCR5 Coreceptor Utilization by the HIV Quasispecies Increases over Time, But Is Not Associated with Disease Progression

被引:0
|
作者
Redd, Andrew D. [2 ]
Laeyendecker, Oliver [1 ,2 ]
Kong, Xiangrong [3 ]
Kiwanuka, Noah [4 ,5 ,6 ]
Lutalo, Tom [4 ]
Huang, Wei [7 ]
Gray, Ronald H. [3 ]
Wawer, Maria J. [3 ]
Serwadda, David [6 ]
Eshleman, Susan H. [1 ]
Quinn, Thomas C. [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA
[2] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
[3] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA
[4] Rakai Hlth Sci Program, Rakai Dist, Uganda
[5] Uganda Virus Res Inst, Entebbe, Uganda
[6] Makerere Univ, Sch Publ Hlth, Kampala, Uganda
[7] Monogram Biosci Inc, San Francisco, CA USA
基金
美国国家卫生研究院;
关键词
SYNCYTIUM-INDUCING VARIANTS; T-CELLS; VIRUS; INFECTION; TROPISM; RAKAI; EVOLUTION; AIDS;
D O I
10.1089/aid.2011.0006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CCR5 is the primary coreceptor for HIV entry. Early after infection, the HIV viral population diversifies rapidly into a quasispecies. It is not known whether the initial efficiency of the viral quasispecies to utilize CCR5 is associated with HIV disease progression or if it changes in an infected individual over time. The CCR5 and CXCR4 utilization efficiencies (R5-UE and X4-UE) of the HIV quasispecies were examined using a pseudovirus, single-round infection assay for samples obtained from known seroconverters from Rakai district, Uganda (n = 88). Initial and longitudinal R5-UE values were examined to assess the association of R5-UE with HIV disease progression using multivariate Cox proportional hazard models. Longitudinal samples were analyzed for 35 seroconverters who had samples available from multiple time points. There was no association between initial or longitudinal changes in R5-UE and the hazard of HIV disease progression (p = 0.225 and p = 0.942, respectively). In addition, R5-UE increased significantly over time after HIV seroconversion (p < 0.001), regardless of HIV subtype or the emergence of CXCR4-tropic virus. These data demonstrate that the R5-UE of the viral quasispecies early in HIV infection is not associated with disease progression, and that R5-UE levels increase in HIV-infected individuals over time.
引用
收藏
页码:289 / 294
页数:6
相关论文
共 50 条
  • [1] The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression
    Paxton, WA
    Kang, S
    Koup, RA
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 : S89 - S92
  • [2] Endocytosis and recycling of the HIV coreceptor CCR5
    Signoret, N
    Pelchen-Matthews, A
    Mack, M
    Proudfoot, AEI
    Marsh, M
    JOURNAL OF CELL BIOLOGY, 2000, 151 (06): : 1281 - 1293
  • [3] HIV coreceptor switch induced by antagonism to CCR5
    Moncunill, Gemma
    Armand-Ugon, Mercedes
    Clotet, Bonaventura
    Este, Jose A.
    ANTIVIRAL RESEARCH, 2007, 74 (03) : A66 - A67
  • [4] Evolution of coreceptor utilization to escape CCR5 antagonist therapy
    Zhang, Jie
    Gao, Xiang
    Martin, John
    Rosa, Bruce
    Chen, Zheng
    Mitreva, Makedonka
    Henrich, Timothy
    Kuritzkes, Daniel
    Ratner, Lee
    VIROLOGY, 2016, 494 : 198 - 214
  • [5] Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
    Yost, Raymond
    Pasquale, Timothy R.
    Sahloff, Eric G.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (08) : 715 - 726
  • [6] New CCR5 variants associated with reduced HIV coreceptor function in southeast Asia
    Capoulade-Métay, C
    Ma, LY
    Truong, LX
    Dudoit, Y
    Versmisse, P
    Nguyen, NV
    Nguyen, M
    Scott-Algara, D
    Barré-Sinoussi, F
    Debré, P
    Bismuth, G
    Pancino, G
    Theodorou, I
    AIDS, 2004, 18 (17) : 2243 - 2252
  • [7] Vitamin E supplementation increases the expression of the CCR5 coreceptor in HIV-1 infected subjects
    PierrePortales
    Guerrier, T
    Clot, J
    Corbeau, P
    Mettling, C
    Lin, YL
    Baillat, V
    de Boever, CM
    Moing, VL
    Tramoni, C
    Reynes, J
    Segondy, M
    CLINICAL NUTRITION, 2004, 23 (05) : 1244 - 1245
  • [8] Genetic polymorphism of CCR5 gene and HIV disease:: the heterozygous (CCR5/Δccr5) genotype is neither essential nor sufficient for protection against disease progression
    Morawetz, RA
    Rizzardi, GP
    Glauser, D
    Rutschmann, O
    Hirschel, B
    Perrin, L
    Opravil, M
    Flepp, M
    von Overbeck, J
    Glauser, MP
    Ghezzi, S
    Vicenzi, E
    Poli, G
    Lazzarin, A
    Pantaleo, G
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (12) : 3223 - 3227
  • [9] HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism
    Zhang, LQ
    Carruthers, CD
    He, T
    Huang, YX
    Cao, YZ
    Wang, G
    Hahn, B
    Ho, DD
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (16) : 1357 - 1366
  • [10] Interactions of CCR5, the Main HIV Coreceptor, with Rantes and Other Ligands
    Morin, Sebastien
    Nisius, Lydia
    Wiktor, Maciej
    Kebbel, Fabian
    Stahlberg, Henning
    Sass, Hans Juergen
    Grzesiek, Stephan
    BIOPHYSICAL JOURNAL, 2012, 102 (03) : 239A - 240A